Stay updated with breaking news from Mutational Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.
Mucopolysaccharidosis VI (MPS VI) is an autosomal recessive lysosomal storage disease caused by mutations in the arylsulfatase B gene (ARSB) and consequent deficient activity of ARSB, a lysosomal enzyme involved in glycosaminoglycan (s) (GAGs) metabolism. Here we present the results study of ARSB DNA analysis in MPS VI patients in the Russian Federation (RF) and other republics of Former Soviet Union. In a cohort of 68 patients (57 families) with MPS VI, a total of 28 different pathogenic alleles were found. The most prevalent nucleotide changes included c.194C>T (Ser65Phe) and c.454C>T ...